Literature DB >> 25549143

The utility of immunohistochemistry in the differential diagnosis of gynecologic disorders.

Hanna G Kaspar1, Christopher P Crum.   

Abstract

CONTEXT: Immunohistochemistry has assumed an increasing role in the identification and characterization of gynecologic disorders including lesions with deceptively bland morphology, uncommon and underdiagnosed neoplasms, and neoplasms with specific genetic alterations associated with overexpression or loss of expression of specific proteins. The diagnostic accuracy has been significantly improved owing to the discovery and increasing experience with the tumor-associated biomarkers, and the increasing demand for precise tumor classification to assess suitability for the expanding therapeutic modalities including clinical trials.
OBJECTIVE: To differentiate lesions of the gynecologic tract through the use of effective immunohistochemical panels. DATA SOURCES: Literature review and authors' personal practice experience.
CONCLUSIONS: The application of diagnostic and prognostic immunohistochemical panels has enabled pathologists to better guide therapeutic decisions and to better predict the clinical outcome. It is now well established that the use of ancillary testing, including immunohistochemistry, has a significant power in the identification, differentiation, and classification of reactive, premalignant, and malignant gynecologic disorders. This article discusses the utilities and pitfalls of the commonly used immunohistochemical markers in the context of overlapping morphologic features encountered in the uterus, ovaries, and fallopian tubes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25549143     DOI: 10.5858/arpa.2014-0057-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

1.  Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Authors:  Rebecca C Arend; Michael D Toboni; Allison M Montgomery; Robert A Burger; Alexander B Olawaiye; Bradley J Monk; Thomas J Herzog
Journal:  Oncologist       Date:  2018-08-23

Review 2.  Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.

Authors:  Juliet E Wolford; Erin Ferrigni; Daniel Margul; Thomas J Herzog
Journal:  Curr Oncol Rep       Date:  2022-03-26       Impact factor: 5.945

Review 3.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.

Authors:  Steffen Hauptmann; Katrin Friedrich; Raymond Redline; Stefanie Avril
Journal:  Virchows Arch       Date:  2016-12-27       Impact factor: 4.064

4.  Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.

Authors:  Anna Schuh; Helene Dreau; Samantha J L Knight; Kate Ridout; Tuba Mizani; Dimitris Vavoulis; Richard Colling; Pavlos Antoniou; Erika M Kvikstad; Melissa M Pentony; Angela Hamblin; Andrew Protheroe; Marina Parton; Ketan A Shah; Zsolt Orosz; Nick Athanasou; Bass Hassan; Adrienne M Flanagan; Ahmed Ahmed; Stuart Winter; Adrian Harris; Ian Tomlinson; Niko Popitsch; David Church; Jenny C Taylor
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

Review 5.  Diagnostic challenges in the gray-zone lesions of fine-needle aspiration cytology.

Authors:  Shruti Gupta; Pranab Dey
Journal:  Cytojournal       Date:  2021-09-10       Impact factor: 2.091

6.  Inter-component immunohistochemical assessment of proliferative markers in uterine carcinosarcoma.

Authors:  Andrzej Pyra; Aneta Adamiak-Godlewska; Dorota Lewkowicz; Beata Bałon; Marek Cybulski; Anna Semczuk-Sikora; Andrzej Semczuk
Journal:  Oncol Lett       Date:  2022-08-31       Impact factor: 3.111

7.  Pure ovarian dysgerminoma in a postmenopausal patient: A case report and review of the management.

Authors:  Jennifer Vaz; Alexandra Mulliken; Nivin Omar; Jessa Suhner; Bogna Brzezinska; Thomas Cotter; Patel Nikhil; Robert V Higgins; Bunja Rungruang
Journal:  Gynecol Oncol Rep       Date:  2022-09-17

8.  Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics.

Authors:  Felix Leung; Marcus Q Bernardini; Kun Liang; Ihor Batruch; Marjan Rouzbahman; Eleftherios P Diamandis; Vathany Kulasingam
Journal:  F1000Res       Date:  2018-02-14

9.  Angiogenin and MMP-2 as potential biomarkers in the differential diagnosis of gestational trophoblastic diseases.

Authors:  Dan Weng; Tao Han; Jin Dong; Ming Zhang; Yang Mi; Yiping He; Xiaojuan Li; Xiaoming Zhu
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.